Ionis Pharmaceuticals ROA - Return on Assets 2010-2024 | IONS

Ionis Pharmaceuticals return on assets for the quarter ending December 31, 2024 was -16.04.

  • Ionis Pharmaceuticals average return on assets for 2023 was -13.24, a 216.75% increase from 2022.
  • Ionis Pharmaceuticals average return on assets for 2022 was -4.18, a 73.89% increase from 2021.
  • Ionis Pharmaceuticals average return on assets for 2021 was -16.01, a 285.78% decline from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.

Ionis Pharmaceuticals ROA - Return on Assets 2010-2024 | IONS

  • Ionis Pharmaceuticals average return on assets for 2023 was -13.24, a 216.75% increase from 2022.
  • Ionis Pharmaceuticals average return on assets for 2022 was -4.18, a 73.89% increase from 2021.
  • Ionis Pharmaceuticals average return on assets for 2021 was -16.01, a 285.78% decline from 2020.

Roa - return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$79.9B
Zoetis (ZTS)$70.1B
Daiichi Sankyo, - (DSNKY)$43.9B
Takeda Pharmaceutical (TAK)$43.7B
Sandoz Group AG (SDZNY)$20.6B
Merck (MKKGY)$18.3B
Astellas Pharma (ALPMY)$17.4B
United Therapeutics (UTHR)$17B
Summit Therapeutics (SMMT)$15.9B
Shionogi (SGIOY)$12.3B
Neurocrine Biosciences (NBIX)$11.4B
Corcept Therapeutics (CORT)$7.7B
Madrigal Pharmaceuticals (MDGL)$7.5B
Orion OYJ (ORINY)$7.4B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Stevanato Group S.p.A (STVN)$6.2B
Grifols, S.A (GRFS)$5.1B
Ono Pharmaceutical (OPHLF)$4.7B
Recursion Pharmaceuticals (RXRX)$4.2B
Crinetics Pharmaceuticals (CRNX)$3.4B
Catalyst Pharmaceuticals (CPRX)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.4B
Hypermarcas (HYPMY)$2.2B
Centessa Pharmaceuticals (CNTA)$2.1B
Soleno Therapeutics (SLNO)$2B
BioCryst Pharmaceuticals (BCRX)$1.9B
NewAmsterdam Pharma (NAMS)$1.8B
Evotec AG (EVO)$1.6B
Ardelyx (ARDX)$1.5B
Indivior (INDV)$1.5B